Chronic Myelogenous Leukemia In Chronic Phase Cml Cp clinical trials

Explore recruiting chronic myelogenous leukemia in chronic phase cml cp clinical trials.

Recruiting chronic myelogenous leukemia in chronic phase cml cp studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Chronic Myelogenous Leukemia In Chronic Phase Cml Cp trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A phase IIIb, multi-center, open-label, treatment optimization study of oral asciminib in patients with Chronic Myelogenous Leukemia in chronic phase (CMLCP) previously treated with 2 or more tyrosine kinase inhibitors

Spain, France, Poland, Germany, Italy, Austria +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase 2, multi-center, open-label, randomized study of oral asciminib added to imatinib versus continued imatinib versus switch to nilotinib in patients with CML-CP who have been previously treated with imatinib and have not achieved deep molecular response

France, Spain, Italy, Czechia, Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

Chronic Myelogenous Leukemia In Chronic Phase Cml Cp trials by city

Chronic Myelogenous Leukemia In Chronic Phase Cml Cp clinical trials

Recruiting chronic myelogenous leukemia in chronic phase cml cp studies right now

A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs

A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.

Study of Olverembatinib (HQP1351) in Patients With CP-CML

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

Asciminib Roll-over Study

Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.

Phase I Trial of Vididencel in CML-CP Patients With MRD Under TKI Treatment

ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase

Also recruiting in Europe

A phase IIIb, multi-center, open-label, treatment optimization study of oral asciminib in patients with Chronic Myelogenous Leukemia in chronic phase (CMLCP) previously treated with 2 or more tyrosine kinase inhibitors

A phase 2, multi-center, open-label, randomized study of oral asciminib added to imatinib versus continued imatinib versus switch to nilotinib in patients with CML-CP who have been previously treated with imatinib and have not achieved deep molecular response

Chronic Myelogenous Leukemia In Chronic Phase Cml Cp trials by city

Other conditions